Nicotine abuse vaccine - Biota Pharmaceuticals
Alternative Names: 3'-aminomethyl-Nic r-EPA Conjugate; Nicotine conjugate vaccine - Nabi Biopharmaceuticals; NicVAXLatest Information Update: 05 Nov 2023
At a glance
- Originator Nabi Biopharmaceuticals
- Developer Aktiv-Dry; Aviragen Therapeutics; Nabi Biopharmaceuticals
- Class Drug withdrawal therapies; Smoking cessation therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Smoking withdrawal
Most Recent Events
- 08 Nov 2012 Biota Holdings has merged with Nabi Biopharmaceuticals to form Biota Pharmaceuticals
- 17 Oct 2012 Efficacy and adverse events data from a phase II trial in Smoking withdrawal reported by Nabi Biopharmaceuticals
- 11 May 2012 Nabi Biopharmaceuticals completes a phase III trial in Smoking withdrawal in USA (NCT01375933)